High-dose Aumolertinib as First-line Treatment in Patients With Brain Metastases Associated With EGFR Mutated NSCLC

HFCAS OpenIR

	High-dose Aumolertinib as First-line Treatment in Patients With Brain Metastases Associated With EGFR Mutated NSCLC
	Fan, Y.
	2022-09-01
发表期刊	JOURNAL OF THORACIC ONCOLOGY
ISSN	1556-0864
关键词	NSCLC EGFR TKI Brain Metastases
收录类别	SCI
语种	英语
WOS研究方向	Oncology ; Respiratory System
WOS类目	Oncology ; Respiratory System
WOS记录号	WOS:000858678101180
出版者	ELSEVIER SCIENCE INC
引用统计
文献类型	期刊论文
条目标识符	http://ir.hfcas.ac.cn:8080/handle/334002/129810
专题	中国科学院合肥物质科学研究院
作者单位	Univ Chinese Acad Sci, Canc Hosp, Hangzhou, Peoples R China
推荐引用方式 GB/T 7714	Fan, Y.. High-dose Aumolertinib as First-line Treatment in Patients With Brain Metastases Associated With EGFR Mutated NSCLC[J]. JOURNAL OF THORACIC ONCOLOGY,2022,17.
APA	Fan, Y..(2022).High-dose Aumolertinib as First-line Treatment in Patients With Brain Metastases Associated With EGFR Mutated NSCLC.JOURNAL OF THORACIC ONCOLOGY,17.
MLA	Fan, Y.."High-dose Aumolertinib as First-line Treatment in Patients With Brain Metastases Associated With EGFR Mutated NSCLC".JOURNAL OF THORACIC ONCOLOGY 17(2022).